The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.

The firm will use the funds to test its NaPi2b-targeted ADC in earlier lines of treatment and across tumor types, and another ADC in 5T4-expressing solid tumors.

The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.

Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying ...

The cell and gene therapy manufacturing company will provide services to advance early-stage translational R&D at Mass General Brigham.

There was strong uptake of Rybrevant-Lazcluze in first-line advanced, EGFR-mutated NSCLC after the combo bested AstraZeneca's Tagrisso in the MARIPOSA trial.

The company is studying the mRNA tumor-associated antigen vaccine as a monotherapy and in combination with Keytruda.

The firm originally filed a BLA in 2023, but the FDA twice delayed its approval decision on the gene therapy and requested more CMC information.

Severe gastrointestinal inflammation could occur in 2 percent to 3 percent of patients who receive Carvykti, the FDA has informed patients and doctors.

The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...

The drugmaker said it plans to submit a regulatory application for DB-OTO to the FDA later this year, pending discussions with the agency.

The initiative comprises academic institutions, charities, and companies pursuing a broad range of novel diagnostic and ...